Celldex Therapeutics Inc. (CLDX)

2.48
NASDAQ : Health Technology
Prev Close 2.51
Day Low/High 2.42 / 2.53
52 Wk Low/High 2.01 / 11.62
Avg Volume 151.10K
Exchange NASDAQ
Shares Outstanding 15.02M
Market Cap 37.70M
EPS -14.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Stock-Picking Wins the Day

There's still speculative interest out there.

4 Stocks Spiking on Unusual Volume

4 Stocks Spiking on Unusual Volume

Often when above-average volume moves into an equity, it precedes a large spike in volatility.

Bulls Deserve Respect

It really is amazing how this market keeps roaring back.

4 Stocks Spiking on Big Volume

4 Stocks Spiking on Big Volume

Unusual volume can be a major signal that hedge funds and momentum traders are piling into a stock ahead of a catalyst.

Cramer's Top Stock Picks: CLDX OXY TEAR TSLA

Cramer's Top Stock Picks: CLDX OXY TEAR TSLA

Celldex and Tearlab are speculative but might be worth the investment and Occidental Petroleum is worth more in parts, Cramer said, but don't buy Tesla stock.

Cramer's 'Mad Money' Recap: Next Week's Game Plan

Cramer's 'Mad Money' Recap: Next Week's Game Plan

The markets will continue to live in a bizarre world where any good economic news will spook institutional traders and send the markets back into a tailspin, Cramer said.

Miss CLDX's $7.50 Offering But Think It's A Buy At $7?

Miss CLDX's $7.50 Offering But Think It's A Buy At $7?

Looking back to 114 days ago, Celldex Therapeutics, Inc. priced a 12,000,000 share secondary stock offering at $7.50 per share.

Bullish Convergences Tend to Yield Strong Trends

In the current scenario, the upside might expand through all major instruments, perhaps lifting the S&P 500 above 1700.

5 Stocks Poised for Breakouts

5 Stocks Poised for Breakouts

These stocks look ready to break out and trade higher from current levels.

Biotech Stock Mailbag: Celldex, TG Therapeutics, Sarepta

Biotech Stock Mailbag: Celldex, TG Therapeutics, Sarepta

Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.

Celldex Reports Fourth Quarter And Fiscal 2012 Financial Results

Celldex Reports Fourth Quarter And Fiscal 2012 Financial Results

Management to Host Conference Call to Discuss Results and Provide 2013 Outlook Today, Thursday, March 7, at 8:30 a.m. Eastern Time

Positive Data From Celldex's Phase 1 Study Of CDX-301 Support Initiation Of Pilot Study In Hematopoietic Stem Cell Transplantation

Positive Data From Celldex's Phase 1 Study Of CDX-301 Support Initiation Of Pilot Study In Hematopoietic Stem Cell Transplantation

Final Study Results Presented in an Oral Session at the 2013 BMT Tandem Meetings

Biotech Stock Mailbag: Dynavax, ImmunoCellular, Celldex and Medgenics

Biotech Stock Mailbag: Dynavax, ImmunoCellular, Celldex and Medgenics

Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.

Too Much Chop

I'm eager to enter new trades but leery of forcing things.

The Twitterverse's Biotech Stock Picks for 2013

The Twitterverse's Biotech Stock Picks for 2013

TheStreet's readers took to Twitter to offer their biotech stock predictions for 2013.

Celldex Therapeutics’ CDX-301 Safely Mobilizes Hematopoietic Cells In Phase 1 Study; Future Development Planned

Celldex Therapeutics’ CDX-301 Safely Mobilizes Hematopoietic Cells In Phase 1 Study; Future Development Planned

Celldex Therapeutics, Inc. (NASDAQ: CLDX) announced positive results from a Phase 1 multi-dose study of CDX-301 (FMS-like tyrosine kinase-3 ligand) demonstrating that CDX-301 was well-tolerated and can safely and ...

Momentum Is Lacking

Action is a mixed bag so far.

Celldex Targeted Drug Benefits Patients With Aggressive Breast Cancer

Celldex Targeted Drug Benefits Patients With Aggressive Breast Cancer

Final results from a mid-stage study of CDX-011 are being presented Saturday at a breast cancer meeting.

Celldex Targeted Drug Benefits Patients With Aggressive Breast Cancer

Celldex Targeted Drug Benefits Patients With Aggressive Breast Cancer

Final results from a mid-stage study of CDX-011 are being presented Saturday at a breast cancer meeting.

Final Data From Celldex Therapeutic’s CDX-011 Phase 2 Study In Metastatic Breast Cancer Supports Overall Survival Benefit In Patients With High GPNMB Expression

Final Data From Celldex Therapeutic’s CDX-011 Phase 2 Study In Metastatic Breast Cancer Supports Overall Survival Benefit In Patients With High GPNMB Expression

Celldex Therapeutics, Inc. (NASDAQ: CLDX) today announced final results from the Company’s randomized Phase 2b EMERGE study of CDX-011 in patients with glycoprotein NMB (GPNMB)-expressing, advanced,...

TheStreet Quant Rating: D- (Sell)